MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer

뉴스 본문을 불러오고 있어요.

MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer | 웨이프 WAPE

MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer

기사 요약

관련 종목

댓글 —